Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Cyagen Closes $41 Million Series B to Expand Animal Research Model Business

publication date: Feb 26, 2020

Cyagen Biosciences Suzhou closed a $41 million Series B financing that it will use to expand its genetically modified rodent business. The round included investments from funds managed by CMS Capital, two GF Securities entities and Guanghua Investment. Founded in 2011, Cyagen claims to be the world's largest provider of custom-engineered mouse and rat models, offering transgenic, knockout, knock-in, CRISPR, and ES-cell based models. It also offers a comprehensive series of stem cell products for research use, including cell lines, media and differentiation kits. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital